Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
SAB Biotherapeutics, Inc. - Common Stock
(NQ:
SABS
)
4.150
-0.440 (-9.59%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 13, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about SAB Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Why Teva Pharmaceutical Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
April 14, 2023
Gainers SAI.TECH Global Corporation (NASDAQ: SAI) jumped 269% to $5.61 after gaining around 25% on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
April 14, 2023
Via
Benzinga
Why Navidea Biopharmaceuticals Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
↗
April 14, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 318% to $29.80 in pre-market trading after gaining more than 345% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
↗
April 14, 2023
It's time for another dive into the biggest pre-market stock movers with all the latest news traders need to know about for Friday!
Via
InvestorPlace
Nasdaq Rises 2%; Consolidated Communications Shares Spike Higher
↗
April 13, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 300 points on Thursday. The Dow traded up 1.09% to 34,013.93 while the NASDAQ rose 2% to 12,167. The S&P 500,...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
April 13, 2023
Via
Benzinga
Dow Rises Over 100 Points; Delta Air Lines Earnings Miss Views
↗
April 13, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Thursday. The Dow traded up 0.43% to 33,790.58 while the NASDAQ rose 1.36% to 12,091.38. The S&P...
Via
Benzinga
Why ViewRay Shares Are Trading Lower By 32%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
April 13, 2023
Gainers CXApp Inc. (NASDAQ: CXAI) jumped 105% to $3.28 after climbing over 20% on Wednesday.
Via
Benzinga
Why Is SAB Therapeutics Stock Trading Higher Today?
↗
April 13, 2023
SAB Therapeutics (NASDAQ: SABS) shares are trading higher on Thursday after the company said it has been granted Fast Track designation from the FDA for SAB-176 influenza immunotherapy with high...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
April 13, 2023
Via
Benzinga
SAB Biotherapeutics Granted Fast Track Designation from FDA for SAB-176 Influenza Immunotherapy with High Cross-Reactivity to Multiple Strains of Influenza
April 13, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody
↗
April 13, 2023
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those...
Via
Benzinga
SAB Biotherapeutics Announces Appointment of Erick Lucera, CFA to Board of Directors
April 04, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Provides Company Update for Full Year 2022
March 31, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
↗
March 29, 2023
On Wednesday, 81 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
March 27, 2023
On Monday, 89 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
March 24, 2023
On Friday, 469 companies hit new 52-week lows.
Via
Benzinga
SAB Biotherapeutics CEO Eddie Sullivan, PhD, to Present Next Generation Biologics in Immunology at BIO CEO & Investor Conference
January 19, 2023
Conference to take place Feb. 6-9 in New York
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Receives an Additional $8.2 Million in Closeout of DoD Contract
January 18, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics Receives Additional $8.2M In Closeout Of COVID-19 DoD Contract
↗
January 18, 2023
SAB Biotherapeutics (NASDAQ: SABS) has received an additional $8.2 million from the U.S. Department of Defense (DoD) related to the closeout of the discontinued COVID-19 prototype research and...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
January 11, 2023
Via
Benzinga
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
January 10, 2023
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
EXCLUSIVE: SAB Biotherapeutics' Type 1 Diabetes Candidate Moves One Step Closer To Enter Human Trials With Completion Of Toxicology Study
↗
January 10, 2023
SAB Biotherapeutics (NASDAQ: SABS) has completed an IND-enabling GLP-tox study for SAB-142, further progressing the therapeutic to prevent and/or delay onset and progression of type 1 diabetes (T1D)...
Via
Benzinga
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
January 09, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
January 05, 2023
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
↗
December 29, 2022
On Thursday, 116 companies set new 52-week lows.
Via
Benzinga
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
December 15, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
December 07, 2022
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2022
↗
November 29, 2022
Via
Benzinga
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
November 21, 2022
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing
From
SAB Biotherapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
